Corona(Covid 19 vaccine) stock that can explode in 2021
A little-known biotech is trying its hand at developing a coronavirus vaccine. Can it succeed?
over the past year, Vaxart stock has soared over 1,250% because of its spot in the lucrative coronavirus vaccine race.
Its stock performance even outpaced those of biotechs that have already brought their coronavirus vaccines to market, such as Moderna and BioNTech.
In fact, over 30% of Vaxart stock has been sold short.
Vaxart claims to have created an experimental coronavirus vaccine in the form of an oral tablet. One could potentially self-administer the vaccine pill, which is stable at room temperature. This would allow patients to order the vaccine online and have it delivered for at-home use.
At the moment, Vaxart's experimental coronavirus vaccine is only in phase 1 clinical trials, with a new data readout expected by next week.
Unfortunately, it's impossible to conclude how the experimental vaccine will work on humans from animal models. Hence, the candidate's phase 1 data release will likely be a make-or-break moment for Vaxart.
Vaxart is under investigation by both the U.S. Securities and Exchange Commission (SEC) and the Department of Justice (DOJ) for insider trading and inaccurate statements regarding its role in Operation Warp Speed (OWS).
Even though Vaxart has more than $133 million in cash and equivalents with no debt whatsoever, that's not nearly enough to move forward. Right now, it could cost billions of dollars to run a potential coronavirus vaccine through clinical trials involving tens of thousands of participants. The company will likely sell more stock to pay for its research and development (R&D) expenses or apply for grant funding -- just to stay afloat.
Vaxart is far riskier than the other coronavirus vaccine drugmakers out there. Its corporate conduct is under federal investigation, and its vaccine candidate is in far too early a stage to draw any definitive conclusions about.
With a market cap just south of $1 billion, it will undoubtedly become a very undervalued stock if it can bring a coronavirus vaccine to market. Moderna, which has done so, projects $11.7 billion in revenue from its mRNA-1273 vaccine alone. However, the probability of Vaxart achieving anything remotely similar is up for debate.
Short-sellers and passionate bulls will be arguing over the stock for the next year. If you believe in Vaxart's science and have the stomach for a roller-coaster ride, then go for it.
over the past year, Vaxart stock has soared over 1,250% because of its spot in the lucrative coronavirus vaccine race.
Its stock performance even outpaced those of biotechs that have already brought their coronavirus vaccines to market, such as Moderna and BioNTech.
In fact, over 30% of Vaxart stock has been sold short.
Vaxart claims to have created an experimental coronavirus vaccine in the form of an oral tablet. One could potentially self-administer the vaccine pill, which is stable at room temperature. This would allow patients to order the vaccine online and have it delivered for at-home use.
At the moment, Vaxart's experimental coronavirus vaccine is only in phase 1 clinical trials, with a new data readout expected by next week.
Unfortunately, it's impossible to conclude how the experimental vaccine will work on humans from animal models. Hence, the candidate's phase 1 data release will likely be a make-or-break moment for Vaxart.
Vaxart is under investigation by both the U.S. Securities and Exchange Commission (SEC) and the Department of Justice (DOJ) for insider trading and inaccurate statements regarding its role in Operation Warp Speed (OWS).
Even though Vaxart has more than $133 million in cash and equivalents with no debt whatsoever, that's not nearly enough to move forward. Right now, it could cost billions of dollars to run a potential coronavirus vaccine through clinical trials involving tens of thousands of participants. The company will likely sell more stock to pay for its research and development (R&D) expenses or apply for grant funding -- just to stay afloat.
Vaxart is far riskier than the other coronavirus vaccine drugmakers out there. Its corporate conduct is under federal investigation, and its vaccine candidate is in far too early a stage to draw any definitive conclusions about.
With a market cap just south of $1 billion, it will undoubtedly become a very undervalued stock if it can bring a coronavirus vaccine to market. Moderna, which has done so, projects $11.7 billion in revenue from its mRNA-1273 vaccine alone. However, the probability of Vaxart achieving anything remotely similar is up for debate.
Short-sellers and passionate bulls will be arguing over the stock for the next year. If you believe in Vaxart's science and have the stomach for a roller-coaster ride, then go for it.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.